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Abstract
Objective—To investigate the psychometric properties of the Bipolar Prodrome Symptom
Interview and Scale–Prospective (BPSS-P), the first specific interview for emerging bipolar
disorder (BD) symptoms.
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Methods—A total of 205 youth aged 12–23 years and/or their caregivers underwent BPSS-P
interviews: 129 patients with mood-spectrum disorders [depression-spectrum disorder (n = 77),
mood disorder not otherwise specified (NOS) (n = 27), BD-NOS (n = 14), bipolar I disorder (BDI)/bipolar II disorder (BD-II)/cyclothymia (n = 11), 34 with non-mood-spectrum disorders, and 42
healthy controls (HCs)]. We used Cronbach’s α to assess internal consistency; intra-class
correlation (ICC) for inter-rater reliability; Spearman’s rho for convergent validity with the Young
Mania Rating Scale (YMRS), General Behavior Inventory–10-item Mania Form (GBI-M-10), and
Cyclothymic–Hypersensitive Temperament (CHT) scale; and ANOVAs for discriminatory power
between diagnostic groups.
Results—Internal consistency was good to very good for the BPSS-P Mania (Cronbach’s α =
0.87), Depression (Cronbach’s α = 0.89), and General Symptom indices (Cronbach’s α = 0.74).
Inter-rater reliability was high for the BPSS-P Total score (ICC = 0.939), and BPSS-P Mania (ICC
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= 0.934), Depression (ICC = 0.985), and General (ICC = 0.981) indices. Convergent validity was
large (rho ≥ 0.50) between the BPSS-P Mania Index and YMRS, GBI-M-10, and CHT; BPSS-P
Depression Index and MADRS and CHT; and BPSS-P General Index and GBI-M-10 and CHT.
Expectedly, convergent validity was small (rho = 0.10 to < 0.30) between the BPSS-P Mania
Index and MADRS, and BPSS-P Depression Index and YMRS. Furthermore, the BPSS-P and its
subscales discriminated each patient group from HCs and from non-mood spectrum patients
(except for the BPSS-P General Index). Moreover, the BPSS-P Total score discriminated BDI/BD-II/cyclothymia from depression-spectrum patients, and the BPSS-Mania Index differentiated
all three bipolar-spectrum groups from depression-spectrum patients.
Conclusions—The BPSS-P has good to excellent psychometric properties. Its use across
multiple settings and predictive validity requires further investigation.
Keywords
adolescents; bipolar disorder; children; clinical high risk; early recognition; mania; pediatric;
prevention; prodrome
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Prediction, early intervention, and prevention of bipolar disorder (BD), a chronic, relapsing,
and highly debilitating illness, are preeminent clinical and research goals (1-10). In BD,
familial high-risk research has a relatively long tradition (11-21). However, different from
psychosis high-risk research (22, 23), clinical high-risk approaches in BD have only more
recently gained strong attention (2, 4-10, 24-30). Since the first illness manifestations of BD
seem to emerge before the age of 18 in up to two-thirds of patients with BD (31, 32), early
recognition and intervention efforts have also focused specifically on youth (1, 5-8, 33-35).
However, different from the psychosis high-risk arena where presence of a psychotic
prodrome has been validated with criteria that have yielded transition rates to psychosis
within six months to three years of 10–40% (23) and where targeted intervention trials have
been successful (22), the existence of a sufficiently specific prodrome to BD that would
allow targeted intervention is much less clear (2, 5-10, 25, 26). Identification of a
symptomatic high-risk BD phase is complicated by the complex nature and definition of BD
in general as well as by its potential different symptom presentations in children and
adolescents.
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Critical differences from the clinical high-risk state for psychosis include the potentially
shorter and more complex time course of the symptom development, episodicity of
subsyndromal symptoms and episodes, and the greater number of sub- or suprathreshold
symptoms allowed before a syndromal BD diagnosis is made. For example, while the onset
of non-affective psychotic disorders is predominantly insidious (36), the onset of BD, even
of depressive episodes (37), may be more abrupt. Moreover, whereas the course of
attenuated positive and negative symptoms usually fluctuates relatively little, subsyndromal
mood symptoms are typically intermittent and episodic. Furthermore, importantly, one
attenuated positive psychotic symptom and one full syndromal positive psychotic symptom,
each, suffice to fulfill criteria for the psychosis prodrome and for transition to full psychosis,
respectively (22). Conversely, for full mania, irritability plus at least four B criteria or mood
elevation and at least three B criteria are required (38). This leaves room for a number of
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combinations of sub- and suptrathreshold symptomatology that may be part of a high-risk
status or trajectory toward BD transition. In addition, different from psychosis, several
conditions that are frequently comorbid with BD or that may develop and exist separately,
such as attention-deficit hyperactivity disorder (ADHD), oppositional defiant disorder, or
borderline personality disorder, present with symptoms that can be (co-)rated as mania
symptoms. Finally, a major depressive episode that often precedes schizophrenia-spectrum
disorders as a separate diagnostic entity can already be part of BD, either preceding a first
manic episode or being part of a developing mixed episode (35). One related problem in
youth is that irritability, which cuts across a whole host of pediatric psychiatric disorders,
appears to predominate over classic elated mood states in early onset BD, particularly in prepubertal individuals (39). Additionally, in children and adolescents, irritability is both an A
criterion for depression and for BD (38), and mixed episodes are frequent in youth (40).
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Given these complexities, an important limitation to reliably identifying high-risk BD
individuals has been the lack of specific rating scales and rating scale-based criteria for
defining clinical high-risk states for BD. The problem of lacking specific BD risk rating
instruments is highlighted by the findings of a prospective study of 147 adolescents fulfilling
clinical high-risk criteria for schizophrenia-spectrum psychoses by having attenuated
positive or negative symptoms (41). In this cohort, eight adolescents who eventually
developed bipolar-spectrum disorders did not differ significantly on any baseline symptoms
and neurocognitive measures compared to 24 adolescents who developed schizophreniaspectrum disorders, while both groups differed significantly from the 115 non-converters
(41). That a tool for the assessment of attenuated or emerging mania-like symptoms is
needed is further indicated by three recent studies. In a large German community sample (n
= 3,206), that underwent three follow-up interviews, the predictive value of the number and
persistence of mania-like symptoms for bipolar I disorder (BD-I) or bipolar II disorder (BDII) development was assessed prospectively in a risk sample of 1,565 subjects aged 14–21
years at baseline who were followed for 10 years (42). The authors found a significant doseresponse relationship for persistence and number of both manic and depressive symptoms.
Moreover, in 30–40% of individuals converting to BD-I/BD-II the symptom progression
could be traced back to subthreshold manic and depressive symptoms (42). Furthermore, in
an 18-month study of youth aged 8–11 years old with mood disorders, 48% of 37 children
with depression-spectrum disorders and transient manic symptoms converted to bipolarspectrum disorders [BD-I, BD-II, and bipolar disorder not otherwise specified (NOS)]
compared to 12% of 13 youth with depression-spectrum disorders (43). Finally, based on
retrospective chart review data, Bechdolf and colleagues (3) proposed a constellation of
three BD risk domains, coined Bipolar at Risk (BAR) criteria: (i) sub-threshold mania
symptoms, (ii) depression plus cyclothymic features, and (iii) depression plus genetic risk.
Importantly, these BAR criteria were recently validated in a prospective study of youth and
young adults aged 15–24 years (44), finding the greatest predictive value in attenuated
mania-like symptoms, further calling for a specific and validated instrument that can be used
to elicit and rate attenuated mania-like as well as other symptoms that may predict the
development of BD.
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Using symptom ratings for a BD risk definition is not new. For example, the self-report or
parent-reported General Behavior Inventory (GBI) (45) was developed to look for
subsyndromal and prodromal presentations of mood disorders, and several decades of
research from multiple groups found evidence that the GBI identifies patients with BD,
correlates plausibly with biomarkers, differentiates patients with BD from other psychiatric
populations or healthy controls, predicts BD development prospectively, and predicts
concurrent diagnoses of cyclothymia and dysthymia (46-59). Recently, prospective data
from the ongoing Longitudinal Assessment of Mania Study (LAMS) (60, 61) revealed that
manic-like symptoms, measured with the Parent General Behavior Inventory–10-item Mania
Form (GBI-M-10) (62), significantly decreased over the two-year follow-up period in the
621 children whose parents/guardians’ ratings scored ≥ 12 on the GBI-M-10 and in the
matched random sample of 86 children whose GBI-M-10 scores were ≤ 11 (63). Altogether,
85% of the cohort experienced decreases in manic symptoms, whereas approximately 15%
either had high and rising, or unstable manic symptoms using the GBI. Importantly, the two
latter patterns were associated with the highest rates of diagnostic conversion to BD (63).
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Conversely, although a meta-analytic review of seven studies using the Child Behavior
Checklist (CBCL) (64) led to the proposal of a constellation of problems with attention,
aggression and anxiety/depression as defining a pediatric BD phenotype, this possibility was
rejected after the majority of subsequent cross-sectional and longitudinal studies (65-71) did
not support the CBCL or the pediatric BD subscale sum score as standardized measures
enabling the differentiation of BD from other psychopathology.
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Finally, a number of studies employed a combination of mania and depression interviews
using psychopathology-based ratings of mild to moderate symptom levels to define at-risk
populations for BD. This approach capitalizes on the dimensional nature of mood ratings
that have been found to be superior to categorical approaches in predicting for example
major depressive disorder (72, 73). Likewise, studies that used composite definitions
combining moderate scores on the Young Mania Rating Scale (YMRS) (80) and Children’s
Depression Rating Scale (CDRS), sometimes with additional criteria such as functional
impairment or family history, found reasonable high rates of progression to bipolarspectrum disorders (16, 43, 63). However, since the YMRS, CDRS, and other mania or
depression scales do not cover all DSM symptoms and use inconsistent anchors and
weighting within the same instrument, availability of an interview that comprehensively
covers depressive and hypo-/manic and that may predict development of bipolar-spectrum
disorders would be valuable.
Taken together, the successful application of the clinical high-risk approach in the psychosis
risk arena (22, 23) through the use of validated rating scales for attenuated positive,
negative, general and basic symptoms (74-76), and the results from the reviewed studies that
point to the relevance of mania-like symptoms for conversion to BD underscore the need for
a validated interview and rating scale for symptoms that may be present prior to the onset of
a first full mania episode and that can be used as a clinical risk prediction tool. Such an
interview would be complementary to the GBI that is a self-rating instrument. Therefore, as
the next step after working with our Bipolar Prodrome Symptom Scale–Retrospective
(BPSS-R) (25), we developed and tested the psychometric properties of the Bipolar
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Prodrome Symptom Interview and Scale–Prospective (BPSS-P) in a group of adolescents
and young adults diagnosed with mood-spectrum and non-mood spectrum psychiatric
disorders as well as in healthy control subjects.

Methods
Participants
Altogether, 205 participants were drawn from two independent samples for this validation
study. The research protocol for the two studies from which the patients were drawn was
approved by the Institutional Review Board at North Shore–Long Island Jewish Health
System (NS-LIJHS). Written, informed consent was obtained from the patient if they were
18 years or older, or from their parent (with patient’s written assent) if the patient was under
18 years of age.
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The first sample (n = 134) consisted of 92 patients at clinical high-risk (CHR) for psychosis
and 42 healthy control subjects (HCs) with available BPSS-P data. Subjects were recruited
to the Zucker Hillside Hospital Recognition and Prevention (RAP) Program from 2006–
2010. The RAP Program is a longitudinal research program for adolescents and young
adults considered to be at CHR for schizophrenia. Patients were referred to the program
from the outpatient and inpatient services at The Zucker Hillside Hospital, a semi-urban,
tertiary care psychiatric hospital, schools, community professionals, and concerned family
members. Patients aged 12–25 years old were included in the RAP program if they met
criteria for one of two CHR categories that were based on scores from the Scale of
Prodromal Symptoms (SOPS) (75). Patients were classified as CHR Negative (CHR−) if
they had a score of moderate or higher (score of 3–6) on any negative symptom (and no
attenuated positive symptoms) or as CHR Positive (CHR+) if they had attenuated positive
symptoms, defined by a score of moderate to severe (score of 3–5) on any SOPS positive
symptom item. Patients were excluded from the study if they met DSM-IV (38) criteria for
an Axis I schizophrenia-spectrum disorder (i.e., schizophrenia, schizoaffective disorder,
schizophreniform disorder, delusional disorder, or psychotic disorder NOS), major
depressive disorder (MDD) with psychotic features, or a bipolar-spectrum disorder (i.e., BDI, BD-II) with psychotic features at baseline. Additionally, patients were excluded if they
were non-English speaking, had a medical or neurological disorder that could affect brain
functioning, drug or alcohol dependence within the past six months, or had an estimated IQ
< 70. HCs had to meet the same criteria, with the exception that they could not meet criteria
for any high-risk category and that they must not have a first-degree relative with a
psychotic disorder. HCs could not have had any lifetime history of psychiatric diagnoses or
psychotropic prescriptions. However, if disruptive behavior disorders and anxiety disorders
were diagnosed during the HC assessment in these non-help-seeking subjects, these
diagnoses were allowed in order to avoid the ascertainment of supernormal controls.
The second sample consisted of 71 patients with available BPSS-P data who were drawn
from the first 103 subjects who were recruited into the ongoing Adolescent Mood Disorder
and Psychosis Study (AMDS) between September 2009 and February 2012. AMDS is a
longitudinal cohort study aiming to characterize the early, pre-syndromal stages of mood
and psychotic disorders in adolescents and young adults. Enrolled are patients aged 12–18
Bipolar Disord. Author manuscript; available in PMC 2015 August 01.
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years with clinical chart diagnoses of mood-spectrum and psychosis-spectrum disorders,
including BD-I, BD-II, BD-NOS, cyclothymia, MDD, depressive disorder NOS, dysthymia
or mood disorder NOS, schizophrenia, schizoaffective disorder, schizophreniform disorder,
or psychotic disorder NOS. Excluded were subjects unable or unwilling to sign consent (if
age 18) or assent (if younger than age 18), or if the legal guardian did not sign informed
consent if patients were < 18 years old, those non-English speaking, with an estimated IQ <
70, meeting DSM-IV criteria for pervasive developmental disorder, autism spectrum
disorders, or current substance dependence, and patients with a medical condition known to
affect the brain. In addition, for these analyses, patients with an Axis I schizophreniaspectrum disorder (i.e., schizophrenia, schizoaffective disorder, schizophreniform disorder,
delusional disorder, or psychotic disorder NOS) were also excluded because too few such
patients were available.
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BPSS-P interviews in the RAP sample were conducted only in patients or healthy control
adolescents, respectively. In the AMDS sample, both patients and primary caregivers were
interviewed whenever possible (patient and caregiver: n = 38, patient only: n = 32, caregiver
only: n = 1). Interviews of both patients and primary caregivers were preferred in order to
further enhance the accuracy of the ratings, using the higher score in case of incongruent
ratings, following the convention that symptoms are more likely minimized or forgotten than
embellished or invented (12, 77).
Clinical assessments
All interviews for the RAP and AMDS studies were administered by a trained masters- or
doctoral-level psychologist (RAP) and/or medical doctor (AMDS). Axis I diagnoses were
assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I/CV)
(78), with added components from the Kiddie-Schedule for Affective Disorders and
Schizophrenia (79) for childhood disorders not contained in the SCID (e.g., oppositional
defiant disorder, conduct disorder, autism spectrum disorders), interviewing both the patient
and the caregiver separately, integrating the results from the two separate interviews.

NIH-PA Author Manuscript

The BPSS-P (Correll CU, Auther AM, Cornblatt BA. The Bipolar Prodrome Symptom
Interview and Scale–Prospective, unpublished manual.) is a semi-structured interview that
was developed based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (38) criteria for BD and MDD, as well as established rating scales for mania,
depression and other psychopathology. In addition, the BPSS-P development was informed
by a review of existing literature regarding risk factors and early symptoms of BD (1),
published scales and interviews for the assessment of the psychotic prodrome and character
traits, input from experts in the areas of the schizophrenia prodrome and BD, and open
questioning of youth with BD and their caregivers regarding emerging subthreshold
symptoms prior to the onset of a first syndromal bipolar manic, mixed and major depressive
episode. Finally, the identified items were used to develop the semi-structured Bipolar
Prodrome Symptom Interview and Scale–Retrospective (BPSS-R) (25). The use of the
BPSS-R in clinical samples of youth and young adults with established BD-I and BD-II
further informed the final BPSS-P development.
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The BPSS-P assesses the onset and severity of prodromal symptoms and is divided into
three sections: Mania, Depression, and General Symptom Index (see Appendix A). The
format of the BPSS-P was modeled after the Scale of Prodromal Symptoms (SOPS) (74),
such that each symptom is rated on the following ordinal scale: 0 = absent, 1 = questionably
present, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe, and 6 = extreme. Each
symptom is assessed by specific probes and anchors for accurate ratings. The severity of the
symptoms is assessed for the past month and the past year. Administration of the BPSS-P
takes about one hour in HCs and 1.5–2.5 hours in psychiatric patients or their caregivers,
depending on the extent and severity of past and current psychopathology.
To test inter-rater reliability, four raters/interviewers at the Masters (n = 1: SS), Ph.D.
psychology (n = 2: AMA, MH), or medical doctor level (n = 1: TK) rated six reliability
video tapes of a patient interview conducted by one of the four expert interviewers (one
interview only contained the ten BPSS-P mania items plus mood lability, a general
psychopathology item). These four raters had been trained on the BPSS-P, using three
training videos and had at least two years (range: 2–6 years) of BPSS-P interview and rating
experience.
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The YMRS (80) was used to measure interviewer-rated manic symptoms. The
Montgomery–Åsberg Rating Scale (MADRS) (81), which was administered in a subgroup
of the AMDS sample (n = 61), was used to measure interviewer-rated depressive symptoms.
The General Behavior Inventory-10-item Mania Form (GBI-M-10) (62) parent and
respective patient self-report, which was added later to the assessment battery of the AMDS
sample (n = 31), was used to measure self-reported mania-like symptoms. Temperament was
measured with the Cyclothymic–Hypersensitive Temperament questionnaire (CHT) (82) of
the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego–Autoquestionnaire
(TEMPS-A) (83).
Statistical analyses

NIH-PA Author Manuscript

For the comparison of the diagnostic groups regarding demographic, illness, and treatment
variables univariate ANOVA with group as the between-subjects factor was conducted for
continuous variables and chi square of Fisher’s Exact test analysis were used for categorical
variables. For the psychometric analyses, the following statistical tests were performed.
Cronbach’s α was used to determine internal consistency of the BPSS Mania, Depression,
and General Index. A Cronbach’s α above 0.70 is considered to be an acceptable cutoff (84),
with a maximum of 0.90 to prevent redundancy (85). The Spearman’s rank correlation
coefficient (rho) was used to determine convergent validity between the BPSS subscales and
four clinical measures: the YMRS, GBI-M-10, MADRS, and CHT. Since convergent
validity between the BPSS-P Mania Index score and the YMRS versus the GBI-M-10 is of
special interest due to the latter two instruments’ current use in the detection of at-risk
individuals, we also calculated the Spearman’s rho coefficient for the correlation between
the BPSS-P Mania Index and the YMRS excluding healthy controls, as the GBI-M-10 was
only administered to a subgroup of the psychiatric patients. Besides a more equal
comparison, this approach has the advantage of avoiding the possibility of an artificial
inflation of the correlation, as healthy controls are likely to all have low scores in the used
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instruments. Moreover, these instruments will be used for early risk detection in clinical
samples and not in healthy control individuals. Inter-rater reliability was assessed using the
intra-class correlation (ICC) coefficient as a two-way mixed model with absolute agreement.
ICC coefficients reflect the consistency of a measure taking into account variance related to
the time of testing (86). A two-way random model was utilized for consistency between
scores. Scores are interpreted as excellent (ICC ≥ 0.75), fair to good (ICC = 0.40–0.74), and
poor (ICC < 0.40) agreement (86). Finally, for the assessment of the discriminant validity of
the BPSS-P Total score and Mania, Depression, and General subscores, as well as for
YMRS and CHT, univariate ANOVA with group as the between-subjects factor was
conducted. This was followed by post-hoc pair-wise comparisons, using Tukey–Kramer
statistics adjusting for multiple testing. There were insufficient numbers of patients with data
on the GBI-M-10 and MADRS, which had only been administered to a subsample to do the
same for these instruments.
All test were two-sided with alpha set at 0.05, using the Statistical Package for the Social
Sciences (SPSS, Inc., Chicago, IL, USA, Version 16.0) or JMP5 (1998–2003 SAS Institute,
Inc.,).

NIH-PA Author Manuscript

Results
Sample characteristics
Demographic, illness, and treatment characteristics of the 163 psychiatric patients [mean
age: 16.0 ± 1.9 years (range: 12–23 years), 57.5% male, 63.2% White] and 42 HCs (mean
age: 17.3 ± 2.4 years, 40.5% male, 57.1% White) included in the analyses of the
psychometric properties of the BPSS-P are displayed in Table 1. Psychiatric patients were
approximately one year younger than HC subjects and contained also 15–25% more males.
In addition, per design, psychiatric patients had significantly more psychiatric diagnoses and
received significantly more psychotropic medications than HCs.

NIH-PA Author Manuscript

Among the 163 psychiatric patients, 129 (79.1%) had a primary mood spectrum disorder,
and 34 (20.9%) had a primary non-mood spectrum disorder. These two groups differed on
few variables in addition to the diagnoses that depended on the grouping by design. These
significant differences included a higher proportion of males and lower mean number of
psychiatric diagnoses in the non-mood disorder group. Moreover, more non-mood disorder
patients were not on any psychotropic medications at the time of the assessment. While nonpsychotic non-mood disorder patients received significantly less antidepressants, the
prescription of antipsychotics, mood stabilizers, anxiolytics, and stimulants did not differ
significantly from those in mood-spectrum disorder patients.
Demographic, illness and treatment characteristics of the 129 mood-spectrum disorder
patients [mean age: 16.1 ± 1.9 years (range: 13–23 years), 51.5% male, 65.90% White] are
displayed and compared in Table 2. Most patients had a primary depressive-spectrum
diagnosis (59.7%), followed by mood disorder NOS (20.9%), BD-NOS (10.9%), and then
BD-I, BD-II, and cyclothymia (8.5%). There were no differences across the mood-spectrum
disorder groups in addition to the diagnostic differences due to grouping, except for the
proportion of patients diagnosed with disruptive behavior disorders (DBDs) and those
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patients with mood disorder NOS than those with depressive disorders remained significant.
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Psychometric properties of the BPSS-P
Internal consistency—Cronbach’s α was used to determine internal consistency within
each of the subscales of the BPSS-P. Internal consistency estimates were high for the BPSSP Mania (Cronbach’s α = 0.87), Depression (Cronbach’s α = 0.89), and General Symptom
Index (Cronbach’s α = 0.74).
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Convergent validity—Table 3 presents Spearman’s rho and p-values for the convergent
validity between the BPSS-P subscales and the YMRS, GBI-M-10, MADRS and CHT.
Correlations were large (r ≥ 0.50) between the BPSS-P Mania Index and the YMRS, GBIM-10, and CHT; BPSS-P Depression Index and MADRS and CHT; and BPSS-P General
Index and GBI-M-10 and CHT. Correlations were medium (rho = 0.30 to < 0.50) between
the BPSS-P Depression Index and the GBI-M-10, and between the BPSS-P General Index
and both the YMRS and MADRS. Correlations were small (rho = 0.10 to < 0.30) between
the BPSS-P Mania Index and MADRS, and BPSS-P Depression Index and the YMRS.
Reanalyzing the correlation between the BPSS-P Mania Index score and the YMRS in
psychiatric patients only (excluding healthy controls), yielded a medium correlation (rho =
0.35, p < 0.0001, n = 159), which was smaller than the large correlation with the GBI-M-10
(rho = 0.54, p = 0.0045, n = 31).
Inter-rater reliability—Inter-rater reliability was very high for the BPSS-P Total score
(ICC = 0.939), as well as for the BPSS-P Mania (ICC = 0.934), Depression (ICC = 0.985),
and General Symptom Index (ICC = 0.981).
Discriminant validity of the BPSS-P across diagnostic groups—BPSS-P Total
scores were significantly different among the diagnostic groups [F(5,195) = 55.73, p <
0.0001] (Fig. 1A). Post-hoc analyses revealed that BPSS-P Mania Index scores were
significantly higher in each of the four individual mood-spectrum disorder groups compared
to both the non-mood spectrum and HC groups. In addition, the BD-I/BD-II/cyclothymia
group had significantly higher BPSS-P Total scores than the depression-spectrum group, and
the non-mood spectrum had higher scores than HCs.
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BPSS-P Mania Index scores were significantly different among the diagnostic groups
[F(5,204) = 51.20, p < 0.0001] (Fig. 1B). Post hoc analyses revealed that BPSS-P Mania
Index scores were significantly higher in each of the three individual bipolar-spectrum
groups (i.e., BD-I/BD-II/cyclothymia, BD-NOS, and mood disorder NOS) compared to the
depression-spectrum, non-mood spectrum and HC groups. In addition, the depressionspectrum and non-mood spectrum groups held a middle position, having significantly higher
BPSS Mania Index scores than HCs.
BPSS-P Depression Index scores were significantly different among the diagnostic groups
[F(5,201) = 44.00, p < 0.0001] (Fig. 1C). Post-hoc analyses revealed that BPSS-P
Depression Index scores were highest in the depression-spectrum disorder group, with
significantly higher scores than the mood disorder NOS as well as the non-mood spectrum
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and HC groups. In addition, BPSS-P Depression Index scores were significantly higher in
each of the three individual bipolar-spectrum groups (i.e., BD-I/BD-II/cyclothymia, BDNOS, and mood disorder NOS) compared to the non-mood spectrum and HC groups.
Finally, the non-mood spectrum disorder group had significantly higher BPSS-P Depression
scores than HCs.
BPSS-P General Index scores were also significantly different among the diagnostic groups
[F(5,195) = 37.04, p < 0.0001] (Fig. 1D). However, this was solely driven by differences
between each of the psychiatric groups and HCs without any significant differences between
psychiatric groups.
Distribution of the YMRS and CHT questionnaire scores across the diagnostic
groups—YMRS total scores were significantly different among the diagnostic groups
[F(5,199) = 22.86, p < 0.0001]. Post-hoc analyses indicated that all five psychiatric groups
had significantly higher YMRS scores than the HC group (Fig. 2A). Moreover, the BDI/BD-II/cyclothymia and mood disorder NOS groups had significantly higher scores that the
depression-spectrum and non-mood disorder spectrum groups, while the BD-NOS group ad
higher scores than the depression-spectrum group only.

NIH-PA Author Manuscript

Finally, CHT total scores were also significantly different among the groups [F(5,183) =
12.07, p < 0.0001] (Fig. 2B). Again, post-hoc analyses indicated that five psychiatric groups
had significantly higher CHT scores than the HC group. However, none of the psychiatric
groups differed from each other.

Discussion

NIH-PA Author Manuscript

This study in 163 psychiatrically ill adolescents with mood-spectrum disorders (n = 129) and
non-psychotic, non-mood spectrum disorders (n = 34), as well as 42 healthy control subjects
suggests that the BPSS-P has good to excellent psychometric properties. This includes very
high internal consistency (Cronbach’s α = 0.87 and 0.89 for the BPSS-P Mania and
Depression Indices), inter-rater reliability (ICC = 0.934–0.985), and convergent validity (r ≥
0.50 between the BPSS-P Mania Index and the YMRS, GBI-M-10, and CHT; and between
the BPSS-P Depression Index and MADRS and CHT). Moreover, in the psychiatric
population, the correlation was greater between the BPSS-P Mania Index and the selfreported GBI-M-10, which has been used successfully in the risk detection for BD, than
between the BPSS-P Mania Index and the YMRS. In addition, the BPSS-P had good
discriminatory power not only regarding healthy control subjects, but also regarding
depression-spectrum disorder patients as well as in relationship to youth with a variety of
non-mood spectrum psychiatric disorders.
We deliberately included a psychiatric sample consisting of patients with diverse mood and
non-mood, but non-schizophrenia spectrum disorders in order to increase generalizability of
the findings and to test discriminant validity of the BPSS-P and its subscales. In general, the
BPSS-P Total score and each of the subscores were significantly different between each of
the psychiatric groups and HCs, but differences emerged also between psychiatric groups for
the BPSS-P Total and the BPSS-P Mania and Depression Index scores. The BPSS-P Total
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score was highest in the syndromal mania/hypomania group, with discrimination from the
depressive-spectrum disorder group despite the low number of subjects in the former group.
Further, the BPSS-P Total score discriminated all mood disorder groups from the non-mood
disorder psychiatric patients. The BPSS-P Mania Index discriminated each of the three
bipolar-spectrum groups from the depression and non-mood disorder groups. All mood
disorder groups separated on the BPSS-P Depression Index from the non-mood disorder
patients. Although the BPSS-P Depression Index scores were highest in the depressive
spectrum disorder group, the scores only separated from the mood disorder NOS group. This
indicates that depression cuts across unipolar and bipolar spectrum groups, but one also
needs to bear in mind that the number of subjects in the BD-NOS and BD-I/BD-II/
cyclothymia groups was quite small, reducing the power to detect significant differences.

NIH-PA Author Manuscript

In contrast to the BPSS-P Total score and the Mania and Depression Indices, the BPSS-P
General Index only differentiated psychiatric groups from HCs, but not from each other.
Although individual items on the BPSS-P General Index could potentially carry some
predictive power for the development of mania and although these findings need to be
replicated with larger numbers of patients in the bipolar-spectrum groups, these results seem
to suggest that the BPSS-P General Index may be too non-specific to yield relevant
discriminatory power. We will follow up on these results, but suggest keeping at least the
mood lability item (6, 26, 87) in case the BPSS-P General Index will be dropped by some
due to time constraints.
Clearly, long-term studies are needed to determine the predictive validity of the BPSS-P, its
subscales and/or individual items. In this regard, if it is not feasible to administer the full
BPSS-P scale, one could also consider administering only the 10 BPSS-P Mania Index items
plus the BPSS-P General Index mood lability item, forming the BPSS-P-Abbreviated
(BPSS-P-A), which we are currently testing in several settings. Notably, the BPSS-P Mania
Index scores were not only highly correlated with the YMRS, but BPSS-P Mania Index
scores were about three times as high as the YMRS scores in each of the five examined
diagnostic groups. This suggests that the BPSS-P detects considerable symptomatology that
is below the threshold of the syndromal YMRS ratings and anchors. These findings are
reflective of the enrichment of the BPSS-P for attenuated mania-like symptoms.
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Although the GBI (46-59, 63) and the combination of mania and depression symptom
ratings (16, 43, 63) have been used successfully in order to identify individuals at risk for
BD, there is a need for an interview that specifically targets symptoms that may emerge
during a mania prodrome and that could complement these other approaches. Interestingly,
although in one study (82), high ratings on the CHT were predictive of development of
broadly defined bipolar-spectrum presentations in adolescents with MDD, in our sample, the
CHT was unable to differentiate any of the 4 psychiatric groups from each other.
While the findings of this study are relevant and encouraging, the next important step will
need to include longitudinal studies in clinical and familial high-risk individuals in order to
assess the predictive validity of the BPSS-P, its subscales or individual items or clusters for
the development of BD-I/BD-II/cyclothymia. Ideally, such studies should enrich samples for
the presence of additional potential risk markers, including circadian rhythm abnormalities,
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imaging, electrophysiological and/or genetic markers (1, 5-10) in order to increase the
likelihood of conversion to BD-I or BD-II in a reasonable time frame.
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Moreover, prospective studies with sufficient numbers of individuals progressing to BDI/BD-II are needed in order to establish high-risk criteria and thresholds on the BPSS-P for
true BD high-risk individuals. While several groups developed theoretical and staging
models for the BD prodrome (1, 3, 7-10), to date, few BD high-risk criteria have been
proposed and tested. For example, following a large cohort of college students for over eight
years, Lewinsohn et al. (88) defined a subsyndromal bipolar subgroup of youth (mean
baseline age = 16.8 years) by “distinct period of abnormally and persistent elevated,
expansive, or irritable mood, plus >1 manic symptom”. Using such broad criteria, the
conversion rate to BD-I/BD-II after eight years was very low (i.e., 1/48 = 2.1%), whereas
40.9% developed MDD. As mentioned before, based on data from the Australian early
identification program, Bechdolf and colleagues (44) were able to validate their BAR
criteria prospectively, finding that attenuated mania-like symptoms had the greatest
predictive value (44). However, a structured assessment of attenuated mania-like symptoms
and of other potentially predictive, emerging symptomatology was not available to the
authors.
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More refined BD high-risk criteria are also hoped to allow for the successful and ethical
testing of low-risk ameliorative and, potentially even, preventive interventions. For example,
randomized early intervention studies, which have yielded inconclusive results, have largely
been limited to high-risk samples of BD offspring with familial loading plus existing mood
symptoms (33, 34, 89, 90). In these samples, the BD high-risk may not have been
sufficiently imminent. By contrast, the only promising randomized trial mentioned above
that tested Multi-Family Psychoeducational Psychotherapy for BD at-risk individuals was
conducted in 165 children 8–11 years old with mood disorders in whom the high-risk status
for BD was determined using presence of mania-like symptoms (43). This 18-month study
followed 37 children with depression-spectrum disorders and transient manic symptoms, 13
youth with depression-spectrum disorders, and 115 with bipolar-spectrum disorders.
Transient manic symptoms were defined as ≥ 1 DSM-IV mania criterion, except for
irritability, that is distinguishable from ADHD, presence of 1–3 manic-like episodes of
moderate to severe intensity lasting ≥ 4 hours, or presence of ≥ 2 brief episodes of 2–4 hours
duration, evidence of functional impairment, and lack of a bipolar-spectrum disorder (i.e.,
BD-I, BD-II, cyclothymia, or BD-NOS). Patients were randomized to receive Multi-Family
Psychoeducational Psychotherapy for the duration of the study or only for the last six
months, i.e., after a one-year wait-list condition. At 18 months, poorer baseline functioning,
as well as receiving the intervention only after one year, rather than immediately, was
associated with transitioning to a bipolar-spectrum disorder (60% versus 16%). These
findings are the first randomized results suggesting that a psychosocial intervention during a
clinically identified high-risk state for BD may be effective in reducing conversion to
bipolar-spectrum disorders. To enable an extension of these findings in larger studies and
ultimately a clinical application, reliable, valid and practical interview and screening tools
need to be developed and tested. We believe that the sound psychometric properties of the
BPSS-P are one further step in this direction.
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The results of our study need to be interpreted within its limitations. These include the small
sample size of the individual bipolar-spectrum disorder groups and the non-mood disorder
group, lack of test-retest data and lack of data on the predictive validity for subscales or
items of the BPSS-P. The relatively small sample sizes in the psychiatric disorder groups
and only partially available MADRS scores also precluded a multivariate examination of the
degree to which the BPSS-P indices may add discriminatory power beyond the dimensional
assessment of manic and depressive symptoms for distinguishing between mood and nonmood disorders and within mood disorders. Future studies should investigate these issues.
Additional limitations include that all patients were help-seeking, that 50–70% received
psychotropic medications at the time of the assessment and the diagnostic heterogeneity of
the study cohort. However, we consider the focus on help-seeking individuals with a wide
variety of psychopathology and psychotropic treatment a strength, as this reflects clinical
reality in groups of patients who may be at potential risk for BD, increasing the
generalizability and applicability of our findings. Since mood symptoms are more pervasive
in the general population than sub/syndromal psychotic experiences, inclusion of diverse
and enriched psychiatric control groups is highly desirable. Thus, a BD high-risk assessment
instrument needs to be able to differentiate at-risk individuals not from healthy individuals,
but rather from patients with a whole host of psychiatric disorders and comorbidities. In this
regard the BPSS-P and/or its subscales performed well to excellent in differentiating
bipolar-spectrum from depression spectrum and non-psychotic, non-mood spectrum disorder
patients. Conduct of this study in only one center and region could be considered a further
limitation. However, we believe that the findings have external validity, given the fact that
The Zucker Hillside Hospital has a large catchment area of 3.5 million people, is located in a
semi-urban location, drawing from more affluent Long Island population as well as urban
Queens and Brooklyn, areas which are among the most diverse in the US. Moreover,
patients in this study were adolescents or young adults aged 12–23 years old. Although
additional data in patients with a broader age range should be collected, the BPSS-P was
developed for youth and adults, and 39 adult caregivers were also interviewed about the
youths’ symptoms using the informant version of the BPSS-P that is identical, except for
asking about of someone else’s symptoms.
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A further limitation is the possibility of criterion conflation, i.e., the fact that we cannot rule
out that results from the diagnostic interview and the BPSS-R may have influenced each
other. Although the scores of the BPSS-P were discussed as part of a consensus conference
on an item-by-item fashion, independent of the results of the diagnostic interview, the results
found in this study may represent a best case scenario. In order to avoid criterion
contamination, future validation studies should consider having different people conduct the
BPSS-P and a diagnostic interview. On the other hand, it is likely that the BPSS-P will be
utilized together with a diagnostic interview and psychopathology assessments, at least in
research settings. Whether parts of the BPSS-P could ultimately be used alone in clinical
practice would be a later question after predictive validity of the total interview or item
constellations has been established. An abbreviated, self-standing scale with predictive
validity would be desirable, as the time needed to complete the entire interview (1.5–3.0
hours) is relatively long. Therefore, future studies are needed that ascertain the test-retest
reliability and predictive validity of the BPSS-P as well as of the BPSS-P-A that contains
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only the 10 BPSS-P Mania items and the mood lability item from the BPSS-P General
Symptom Index. Should the BPSS-P Mania Index be most predictive, then the research as
well as clinical utility of the much shorter BPSS-P-A scale should be tested more widely.
Moreover, we also recently developed a self-rating instrument of the BPSS-P-A, the BPSSA-Screen in a patient and informant version, which we are currently testing and which may
even have greater feasibility for use in clinical care.
In summary, we present the first semi-structured interview and rating scale for the clinical
risk for BD, showing good to excellent psychometric properties, including discriminatory
power compared to youth with depression-spectrum and non-mood spectrum disorders.
Future, longitudinal studies in samples enriched for BD high-risk are needed to further
assess the utility of the full BPSS-P and of its subscales in the early identification and risk
stratification of help-seeking individuals with symptomatic mood presentations.
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Scale–Prospective (BPSS-P) structure and items
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*

Worsening: Record most recent date when a symptom currently rated 3–5 experienced an increase in intensity by at least
one rating point.
**
Optional items; rate only if not also using the SIPS/SOPS or CAARMS for a more-detailed assessment of prodromal
psychotic symptoms.
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Fig. 1.
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Bar graphs of mean ± standard deviation in the Bipolar Prodrome Symptom Interview and
Scale–Prospective (BPSS-P) Total score (A), BPSS-P Mania Index score (B), BPSS-P
Depression Index score (C), and BPSS-P General Symptom Index score (D) across
diagnostic groups. NOS = not otherwise specified. *p < 0.05 for greater value in post-hoc
pair-wise comparisons adjusted for multiple testing.
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Fig. 2.
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Bar graph of mean ± standard deviation of the Young Mania Rating Scale score (A) and the
Cyclothymic–Hypersensitive Temperament score (B) across diagnostic groups. NOS = not
otherwise specified. *p < 0.05 for greater value in post-hoc pair-wise comparisons adjusted
for multiple testing.
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c
Medication information missing for three patients with mood spectrum disorder.

Other disorders included: unspecified mental disorder (n = 1), intermittent explosive disorder (n = 2), learning disorder (n = 3), pain disorder (n = 1), parent–child relational problem (n = 1), pervasive
developmental disorder (n = 3), communication disorder (n = 1), alcohol use disorder (n = 1), reading disorder (n = 1), bulimia (n = 2), and body dysmorphic disorder (n = 1).

b

Depressive spectrum disorders included: major depressive disorder (n = 51), depressive disorder not otherwise specified (n = 18), dysthymic disorder (n = 4), and adjustment disorder with depressed mood
(n = 4).
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b

Other disorders included: unspecified mental disorder (n = 1), intermittent explosive disorder (n = 2), learning disorder (n = 3), pain disorder (n = 1), parent–child relational problem (n = 1), pervasive
developmental disorder (n = 3), communication disorder (n = 1), alcohol use disorder (n = 1), reading disorder (n = 1), bulimia (n = 2), and body dysmorphic disorder (n = 1).

a

0.24

0.77

0.043

0.53

0.17

0.48

0.12

0.11

0.21

0.17

0.12

0.025

0.51

0.43

0.66

0.32

0.56

0.32

0.56

0.44

0.56

Omnibus p-value

Bolded p-values: p < 0.05. NOS = not otherwise specified; BD-NOS = bipolar disorder not otherwise specified; BD-I = bipolar I disorder; BD-II = bipolar II disorder; SD = standard deviation.

36 (28.6)

None

Psychotropic medications, n (%)b

34 (26.4)

26 (33.8)

4 (5.2)

5 (3.9)
55 (42.6)

5 (6.5)

9 (11.7)

1 (1.3)

4 (5.2)

5 (6.5)

6 (7.8)

7 (9.1)

9 (11.7)

8 (6.2)

Attention-deficit hyperactivity disorder

Disruptive behavior disorders

Substance dependence

Substance abuse

13 (10.1)

10 (7.8)

Other anxiety disorder

Substance use disorders

12 (9.3)

NIH-PA Author Manuscript

Panic disorder

Mood disorder NOS
(n = 27)

NIH-PA Author Manuscript
Depression spectrum
disorders (n = 77)

NIH-PA Author Manuscript

All mood spectrum
disorders (n = 129)
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–
–
–
–
–
–

BPSS-P Depression Index

BPSS-P General Index

YMRS

GBI-M-10

MADRS

CHT

–

–

–

–

–

–

–

–

–

–

–

–

0.56c

0.45a

–

–

0.39e

0.27a

0.72a

–

–

–

–

0.31

0.54c

0.52a

0.65a

GBI-M-10

0.50a

YMRS

BPSS-P General Index

BPSS-P Depression Index

–

–

0.22

–0.24

0.42b

0.69a

0.14

MADRS

–

0.10

0.48d

0.42a

0.55a

0.50a

0.56a

CHT

p < 0.05.

e

p < 0.01;

d

p < 0.005;

c

p < 0.001;

p < 0.0001;

b

a

BPSS-P = Bipolar Prodrome Interview and Symptoms Scale–Prospective; YMRS = Young Mania Rating Scale; GBI-M-10 = General Behavior Index–Mania-10 Item Form; MADRS = MontgomeryÅsberg Depression Rating Scale; CHT = Cyclothymic–Hypersensitive Temperament.

–

BPSS-P Mania Index

BPSS-P Mania Index

Spearman’s rank correlation coefficients (rho) for the BPSS-P subscales and the YMRS, GBI-M-10, MADRS, and the CHT

NIH-PA Author Manuscript
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